CDTX
Income statement / Annual
Last year (2024), Cidara Therapeutics, Inc.'s total revenue was $1.28 M,
a decrease of 94.52% from the previous year.
In 2024, Cidara Therapeutics, Inc.'s net income was -$169.83 M.
See Cidara Therapeutics, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$1.28 M |
$23.28 M |
$64.45 M |
$49.57 M |
$12.07 M |
$20.92 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$0.00
|
$36.76 M
|
$0.00
|
$73.09 M
|
$0.00
|
$46.40 M
|
$523.00 K
|
$667.00 K
|
$732.00 K
|
$461.00 K
|
| Gross Profit |
$1.28 M
|
-$13.48 M
|
$64.45 M
|
-$23.52 M
|
$12.07 M
|
-$25.49 M
|
-$523.00 K
|
-$667.00 K
|
-$732.00 K
|
-$461.00 K
|
| Gross Profit Ratio |
1
|
-0.58
|
1
|
-0.47
|
1
|
-1.22
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$156.76 M
|
$36.76 M
|
$77.41 M
|
$73.09 M
|
$68.02 M
|
$46.40 M
|
$49.14 M
|
$42.82 M
|
$35.70 M
|
$23.48 M
|
| General & Administrative Expenses |
$20.62 M
|
$13.58 M
|
$20.55 M
|
$18.74 M
|
$15.90 M
|
$16.24 M
|
$14.14 M
|
$12.90 M
|
$12.74 M
|
$8.84 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$20.62 M
|
$13.58 M
|
$20.55 M
|
$18.74 M
|
$15.90 M
|
$16.24 M
|
$14.14 M
|
$12.90 M
|
$12.74 M
|
$8.84 M
|
| Other Expenses |
$0.00
|
-$36.76 M
|
$0.00
|
-$73.09 M
|
$0.00
|
$0.00
|
-$211.00 K
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$177.38 M
|
$13.58 M
|
$97.95 M
|
$18.74 M
|
$83.92 M
|
$62.64 M
|
$63.29 M
|
$55.72 M
|
$48.44 M
|
$32.31 M
|
| Cost And Expenses |
$177.38 M
|
$50.34 M
|
$97.95 M
|
$91.83 M
|
$83.92 M
|
$62.64 M
|
$63.29 M
|
$55.72 M
|
$48.44 M
|
$32.31 M
|
| Interest Income |
$5.81 M
|
$2.00 M
|
$191.00 K
|
$0.00
|
$0.00
|
$221.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$262.00 K
|
$0.00
|
$629.00 K
|
$7.00 K
|
$271.00 K
|
$120.00 K
|
| Depreciation & Amortization |
$233.00 K
|
$112.00 K
|
$143.00 K
|
$189.00 K
|
$1.05 M
|
$328.00 K
|
$523.00 K
|
$667.00 K
|
$732.00 K
|
$461.00 K
|
| EBITDA |
-$175.87 M |
-$26.95 M |
-$33.36 M |
-$42.07 M |
-$70.80 M |
-$41.40 M |
-$62.76 M |
-$55.72 M |
-$47.70 M |
-$31.85 M |
| EBITDA Ratio |
-137.94
|
-1.16
|
-0.52
|
-0.85
|
-5.87
|
-1.98
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
-138.12
|
-1.16
|
-0.52
|
-0.85
|
-5.95
|
-1.99
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$5.81 M
|
$2.00 M
|
$191.00 K
|
-$212.00 K
|
-$262.00 K
|
$632.00 K
|
$4.27 M
|
-$7.00 K
|
$271.00 K
|
$120.00 K
|
| Income Before Tax |
-$170.29 M
|
-$25.07 M
|
-$33.31 M
|
-$42.47 M
|
-$72.11 M
|
-$41.09 M
|
-$59.02 M
|
-$55.73 M
|
-$48.17 M
|
-$32.19 M
|
| Income Before Tax Ratio |
-133.56
|
-1.08
|
-0.52
|
-0.86
|
-5.98
|
-1.96
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00
|
$15.00 K
|
$272.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Net Income |
-$169.83 M
|
-$22.93 M
|
-$33.58 M
|
-$42.47 M
|
-$72.11 M
|
-$41.09 M
|
-$59.02 M
|
-$55.73 M
|
-$48.17 M
|
-$32.19 M
|
| Net Income Ratio |
-133.2
|
-0.98
|
-0.52
|
-0.86
|
-5.98
|
-1.96
|
0
|
0
|
0
|
0
|
| EPS |
-26.75 |
-5.25 |
-9.61 |
-16.2 |
-36.03 |
-26.78 |
-45.62 |
-63.69 |
-66.49 |
-46.76 |
| EPS Diluted |
-26.75 |
-5.25 |
-9.61 |
-16.19 |
-36.03 |
-26.78 |
-45.62 |
-63.69 |
-66.49 |
-46.76 |
| Weighted Average Shares Out |
$6.35 M
|
$4.37 M
|
$3.49 M
|
$2.62 M
|
$2.08 M
|
$1.50 M
|
$1.29 M
|
$875.04 K
|
$724.45 K
|
$688.48 K
|
| Weighted Average Shares Out Diluted |
$6.35 M
|
$4.37 M
|
$3.49 M
|
$2.62 M
|
$2.08 M
|
$1.50 M
|
$1.29 M
|
$875.04 K
|
$724.45 K
|
$688.48 K
|
| Link |
|
|
|
|
|
|
|
|
|
|
